Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05814367 · ClinicalTrials.gov registry record · Phase 2
Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops
A Phase 2 study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT05814367: Completed Phase 2 study, sponsored by Johnson & Johnson Vision Care.
NCT05814367 is a Phase 2 study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05814367, a Phase 2 study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This will be a single-visit, multi-site, randomized, single-masked, bilateral, active-controlled, non-dispensing, 2X2 crossover study.
Primary Outcome
Monocular visual acuity was measured at distance (4meter) using a logMAR (Logarithm of Minimal Angle of Resolution) scale under high luminance high contrast lighting conditions. VA was assessed using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual acuity score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of
Interventions
- DRUG Blink® Tears eye drops in a multidose bottle
- DRUG Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2023-05-06 |
| Phase | Phase 2 |
What the finished NCT05814367 record still lists
NCT05814367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Blink® Tears eye drops in a multidose bottle is the first listed.
NCT05814367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05814367 about?
NCT05814367 is a clinical study titled "Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops". This will be a single-visit, multi-site, randomized, single-masked, bilateral, active-controlled, non-dispensing, 2X2 crossover study.
What is the current status of trial NCT05814367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2023-04-06. Estimated completion is 2023-05-06.
What interventions are being tested in trial NCT05814367?
The interventions under investigation include: Blink® Tears eye drops in a multidose bottle (DRUG), Preservative-free investigational lubricating eye drops in a Novelia® eyedropper (DRUG).
Who is sponsoring clinical trial NCT05814367?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05814367's enrollment target sits among peer trials
46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI